Allergic inflammation of the anterior surface of the eye

2020 ◽  
Vol 41 (6) ◽  
pp. 449-453 ◽  
Author(s):  
Leonard Bielory
Keyword(s):  
Allergic Conjunctivitis ◽  
Allergic Inflammation ◽  
Tear Film ◽  
Ophthalmic Solution ◽  
Histamine Receptor ◽  
Oral Medications ◽  
Ocular Itching ◽  
Repurposed Drugs ◽  
New Treatments ◽  
H1 Receptor Antagonist

Background: Ocular allergies affect an estimated 40% of the population, 98% of which are because of allergic conjunctivitis and includes tear film dysfunction. With the current advent of both repurposed drugs for ocular allergies, as well as novel drugs, lubricants and methods of administration, there is a need to update new treatments to optimize the care of ocular allergy patients. Methods: An overview of mediators, clinical characteristics and management is provided in a summary format. Results: Lubricants (best when refrigerated provide immediate relief that is short lived (several minutes) due to its dilutional effect on mediators and pollen in the tear film. Immediate and longer-term benefit occurs from different topical and oral medications ‐ primarily histamine receptor agonists. Conclusion: The newest prescription topical ophthalmic histamine H1 receptor antagonist (an inverse agonist) to be approved by the U.S. Food and Drug Administration in the past 10 years (U.S. NDA approved May 30, 2017) is cetirizine ophthalmic solution for the treatment of ocular itching with allergic conjunctivitis in adults and in children more than 2 years old.

The Expanding Picture of the Clinical Utility of BEPREVE® (Bepotastine Besilate Ophthalmic Solution) 1.5 % in the Treatment of Itch Associated with Allergic Conjunctivitis

2011 ◽  
Vol 04 (02) ◽  
pp. 101
Author(s):  
Richard L Lindstrom ◽  
Keyword(s):  
Allergic Conjunctivitis ◽  
Clinical Utility ◽  
Therapeutic Response ◽  
Ophthalmic Solution ◽  
Trial Data ◽  
Ocular Allergy ◽  
Pivotal Trial ◽  
Exposure Study ◽  
Fda Approval ◽  
Ocular Itching

A new analysis of pivotal trial data and a variety of additional studies completed since US Food and Drug Administration (FDA) approval are broadening our understanding of the clinical utility of BEPREVE® (bepotastine besilate ophthalmic solution) 1.5 % in the treatment of ocular itch associated with allergic conjunctivitis. These results include evidence of a durable therapeutic response of up to 16 hours following a single dose, a comfort profile comparable or superior to other drugs in the class, and robust efficacy against ocular itching and redness in an environmental exposure study model that simulates the patient experience of ocular allergy.

Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis

2012 ◽  
Vol 33 (3) ◽  
pp. 265-274 ◽  
Author(s):  
Edward J. Meier ◽  
Gail L. Torkildsen ◽  
James A. Gow ◽  
Timothy R. McNamara ◽  
Paul J. Gomes ◽  
...  
Keyword(s):  
Allergic Conjunctivitis ◽  
Ophthalmic Solution ◽  
Phase Iii ◽  
Ocular Itching ◽  
Phase Iii Trials

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Ocular Itching in a Clinical Model of Allergic Conjunctivitis

2009 ◽  
Vol 123 (2) ◽  
pp. S57-S57 ◽  
Author(s):  
G.L. Torkildsen ◽  
P.J. Gomes ◽  
J.I. Williams ◽  
J.A. Gow ◽  
T.R. McNamara
Keyword(s):  
Allergic Conjunctivitis ◽  
Ophthalmic Solution ◽  
Clinical Model ◽  
Ocular Itching

Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis

2007 ◽  
Vol 28 (4) ◽  
pp. 427-433 ◽  
Author(s):  
Mark B. Abelson ◽  
Paul J. Gomes ◽  
Terri Pasquine ◽  
Michael R. Edwards ◽  
Robert D. Gross ◽  
...  
Keyword(s):  
Allergic Conjunctivitis ◽  
Ophthalmic Solution ◽  
Signs And Symptoms

scholarly journals Effect of Desonide 0.25% Ophthalmic Solution on Central Corneal Thickness and Intraocular Pressure of Patients with Allergic Conjunctivitis

1970 ◽  
Vol 12 (3) ◽  
pp. 156-158
Author(s):  
Ozlem Gurses Sahin
Keyword(s):  
Intraocular Pressure ◽  
Allergic Conjunctivitis ◽  
Central Corneal Thickness ◽  
Corneal Thickness ◽  
Ophthalmic Solution ◽  
Applanation Tonometry ◽  
Goldmann Applanation Tonometry ◽  
Mean Values ◽  
Conjunctival Hyperaemia ◽  
Significant Difference

Aim: To evaluate whether a significant difference exists between the initial and final mean central corneal thickness that might affect Goldmann applanation tonometer recordings of patients with allergic conjunctivitis treated with desonide 0.25% ophthalmic solution, and to determine the effect of desonide on intraocular pressure by using adjusted intraocular pressure values.Methods: This double-blind randomised placebo-controlled trial enrolled 30 patients (60 eyes) with allergic conjunctivitis. Patients were randomly assigned to receive desonide to 1 eye (study eye) and preservative-free tear supplement (Tears Naturale Free®) to the other eye (control eye) 3 times daily for 3 weeks. Goldmann applanation tonometry and central corneal thickness of both eyes were recorded on the day of presentation and 3 weeks later.Results: Regression of itching, tearing, conjunctival hyperaemia, and tarsal conjunctival papillary reaction were noted in the study eyes after 3 weeks of treatment. The control eyes showed mild regression of pruritis, tearing, conjunctival hyperaemia, and tarsal conjunctival papillary reaction after 3 weeks. There was a significant difference between the initial and final mean central corneal thickness values for the study eyes (p = 0.003). There were no statistically significant differences between the initial and final mean values of Goldmann applanation tonometry and adjusted intraocular pressure for the study eyes. No statistically significant differences were found between the initial and final mean values of any of the parameters for the control eyes.Conclusion: Inflammation-induced increase in central corneal thickness of patients with allergic conjunctivitis treated with desonide showed statistically significant regression. However, this regression did not significantly affect Goldmann applanation tonometry and adjusted intraocular pressure values of the treated eyes.

scholarly journals The problem with treating sinusitis against the background of allergic rhinitis

2019 ◽  
pp. 110-114
Author(s):  
A. I. Kryukov ◽  
A. B. Turovsky ◽  
I. G. Kolbanova ◽  
Yu. V. Luchsheva ◽  
K. M. Musaev ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Allergic Inflammation ◽  
Histamine Receptor ◽  
Receptor Blocker ◽  
Basic Principles ◽  
Financial Costs ◽  
Health Burden ◽  
Histamine Antagonist

Both allergic rhinitis (AR) and sinusitis are widespread diseases that significantly worsen the patient’s quality of life, lead to significant financial costs and are associated with a huge health burden. When treating any AS, it is necessary to follow three basic principles: address the cause of the disease; eradicate the pathogen; restore drainage of sinuses, aerate and restore CO. The efficacy and speed in the treatment of sinusitis, which arose against the background of allergic inflammation, are comparable to those in the use of oral GCS (Ib level, persuasion scale A). The H1-histamine receptor blocker and competitive histamine antagonist ebastine is one of the most effective and safe latest-generation antihistamine.

GLAXO/MRS PAPERRoles of chemokines in the regulation of leucocyte recruitment*

2001 ◽  
Vol 100 (4) ◽  
pp. 359-362
Author(s):  
Ian SABROE ◽  
Timothy J. WILLIAMS ◽  
James E. PEASE
Keyword(s):  
Small Molecules ◽  
Inflammatory Disease ◽  
Chemokine Receptors ◽  
Allergic Inflammation ◽  
New Treatments ◽  
Leucocyte Recruitment

In the search for new treatments for human inflammatory disease, antagonism of chemokine receptors by small molecules is an attractive goal. Although there are overlapping patterns of expression of chemokine receptors between leucocyte types, an investigation of the chemokine responsiveness of cells important in allergic inflammation, such as the eosinophil and the basophil, is beginning to uncover how selective recruitment may be regulated. The story of the eotaxin receptor, CCR3, and its central role in allergic inflammation illustrates that therapeutic antagonism of these pathways is imminently achievable.

Sign in / Sign up

Export Citation Format

Share Document